ReviewDiagnostics (Basel, Switzerland)2020
Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues.
Review in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Seromucinous borderline ovarian tumors: Clinical and ultrasound characteristics and association with endometriosis.Acta obstetricia et gynecologica Scandinavica · 2026Observational
- Article
- Comprehensive Review of Endometriosis Based on Imaging Findings: What Radiologists Need to Know.Journal of the Korean Society of Radiology · 2025Review
- Laparoscopic resection of a giant post-mesenteric ovarian seromucinous cystadenoma: a case report and review.Frontiers in oncology · 2025Article
- Molecular landscape of borderline ovarian tumours: A systematic review.Open medicine (Warsaw, Poland) · 2024Review
- Clinicopathological Characteristics and Prognosis of 91 Patients with Seromucinous and Mucinous Borderline Ovarian Tumors: a Comparative Study.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- Microscopic Evaluation of Ovarian Surface Epithelium Following Treatment with Conjugated Estrogens in a Mouse Model.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Seromucinous Cystadenoma Presenting as Endometriosis Complications in a 57-Year-Old Female: A Case Report.Cureus · 2022Article
- Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.Current oncology (Toronto, Ont.) · 2022Article
- PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis.Journal of ovarian research · 2022Article
- Trousseau's syndrome associated with an ovarian borderline tumour.BMJ case reports · 2021Article
- Ovarian seromucinous tumors: clinicopathological features of 10 cases with a detailed review of the literature.Journal of ovarian research · 2021Review
- Three cases of seromucinous carcinoma of the ovary arising in endometriotic cysts.International cancer conference journal · 2021Article
- Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian seromucinous tumors were introduced in the 2014 World Health Organization (WHO) classification as one of the seven types of ovarian epithelial tumors. They are characterized by frequent association with endometriosis and bilaterality, microscopic appearance of papillary architecture, and admixture of a variety of müllerian-type epithelium. They are considered to be endometriosis-related ovarian neoplasms, along with endometrioid and clear cell tumors; recent molecular studies suggest this particular tumor is a variant of endometrioid tumor. Discrepancies in nomenclature, definition, and morphology of seromucinous tumors appear to be a source of confusion, for both clinicians and general surgicalpathologists. This review summarizes the clinicopathological features of benign, borderline, and malignant seromucinous tumors, as well as controversies regarding these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.